Veeva adds nearly 80 Vault Quality customers, including four of the
top 20 global pharmaceutical companies
PHILADELPHIA, Pa.--(BUSINESS WIRE)--
2016 Veeva R&D Summit – Today at the Veeva
R&D Summit, to an audience of more than 600 industry leaders, Veeva
Systems (NYSE:VEEV) announced broad industry adoption of Veeva
Vault QualityDocs and Veeva
Vault QMS as the life sciences industry focuses on unifying quality
management. Prompted by the need to seamlessly bring together quality
work processes and content management, Veeva has added nearly 80 quality
customers in less than four years and eight customers have signed on for
Vault QMS since the product was released four months ago.
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20161018005689/en/
(Graphic: Business Wire)
Four of the top 20 largest pharmaceutical companies are using Veeva
Vault quality applications to drive greater global alignment,
collaboration with external contract manufacturers and partners, and
harmonization of quality processes. With Veeva, companies get a modern
cloud solution to standardize the flow of information and support
multiple, concurrent outsourcing models, while ensuring process
transparency.
In 2015, the FDA issued warnings to 10 drug companies for data integrity
violations – the most in a decade.1 A mix of disparate legacy
systems add to data integrity challenges by fragmenting internal
processes and making it harder to incorporate global partners. With
increased outsourcing of quality manufacturing and pressure to adhere to
manufacturing regulations, full visibility into quality processes and
supply chains is becoming more critical.
“Collaboration and access across global stakeholders are not only
critical for achieving compliance, but also to ensure data integrity,”
said Craig Gassman, associate director of regulatory operations at
Karyopharm Therapeutics. “With Veeva Vault Quality, all of our partners
have real-time visibility in the cloud and we gain end-to-end control of
critical documents and processes.”
“The demand for Veeva Vault quality applications is indicative of the
industry need to unify quality processes and documentation across
business units and borders,” said Mike Jovanis, vice president of Vault
Quality at Veeva. “Vault’s true multitenant cloud architecture connects
quality-related processes, documents, and stakeholders for better
visibility and collaboration throughout the entire global supply chain.”
Vault QualityDocs and Vault QMS is the only integrated suite of quality
applications for seamless end-to-end content and quality management.
Both applications are built on Veeva
Vault, a proven cloud platform and suite of applications that
provide a single source of truth across the enterprise. Native
interoperability between Vault applications empowers life sciences
companies to streamline their business processes across an increasingly
broad ecosystem of internal and external stakeholders.
In other news today, Veeva announced that ICON is streamlining its
regulatory and quality operations with Veeva Vault applications, and
that inVentiv is expanding its adoption of the Veeva
Vault Clinical Suite to expedite site activation for clients. Read
our press
release for ICON and our press
release for inVentiv to learn more.
Additional Information
For more on the Veeva suite of quality products, visit: veeva.com/quality
For more on Veeva Vault QualityDocs, visit: veeva.com/QualityDocs
For more on Veeva Vault QMS, visit: veeva.com/QMS
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow us @veevasystems on Twitter: twitter.com/veevasystems
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global
life sciences industry. Committed to innovation, product excellence, and
customer success, Veeva has more than 450 customers, ranging from the
world's largest pharmaceutical companies to emerging biotechs. Veeva is
headquartered in the San Francisco Bay Area, with offices in Europe,
Asia, and Latin America. For more information, visit www.veeva.com.
Forward-looking Statements
This release contains forward-looking statements, including the market
demand for and acceptance of Veeva’s products and services, the results
from use of Veeva’s products and services, and general business
conditions, particularly in the life sciences industry. Any
forward-looking statements contained in this press release are based
upon Veeva’s historical performance and its current plans, estimates,
and expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva’s expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva’s financial results are included under the captions,
“Risk Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in the company’s filing on Form
10-Q for the period ended July 31, 2016. This is available on the
company’s website at veeva.com
under the Investors section and on the SEC’s website at sec.gov.
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to
time.
1 (PwC: March 2016), Data Integrity Problems a Growing Risk
to Global Pharma Companies
View source version on businesswire.com: http://www.businesswire.com/news/home/20161018005689/en/
Source: Veeva Systems Inc.